Michael Valitutto, DO
Internal Medicine · Kalamazoo, MINPI 1326074378
Payments from drug & device makers
Across 3,380 payments — averaging $518.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$589K
- Novo Nordisk$360K
- Corcept Therapeutics$233K
- Bayer$182K
- AstraZeneca$99K
- Boehringer Ingelheim$71K
- plus $218K from 28 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 997 | $589,191 |
| Novo Nordisk | 696 | $359,684 |
| Corcept Therapeutics | 278 | $232,770 |
| Bayer | 240 | $182,405 |
| AstraZeneca(2 entities) | 110 | $98,781 |
| Boehringer Ingelheim | 179 | $70,704 |
| Insulet Corporation | 264 | $56,241 |
| Amgen(2 entities) | 108 | $40,984 |
| Sanofi-aventis U.S. LLC | 34 | $23,435 |
| Abbott | 60 | $23,069 |
| Cequr Corporation | 6 | $20,093 |
| GSK | 1 | $12,350 |
| AbbVie | 18 | $10,472 |
| Dexcom, Inc. | 79 | $8,795 |
| Valeritas, Inc. | 45 | $7,417 |
| Madrigal Pharmaceuticals | 24 | $5,346 |
| Mannkind Corporation | 61 | $4,606 |
| Zealand Pharma US, Inc. | 10 | $2,179 |
| Tandem Diabetes Care, Inc. | 55 | $1,073 |
| Regeneron Healthcare Solutions, Inc. | 2 | $648 |
| Novartis | 53 | $590 |
| Johnson & Johnson | 37 | $499 |
| Medtronic(2 entities) | 4 | $180 |
| Ascensia Diabetes Care US Inc. | 1 | $98 |
| Neurocrine Biosciences, Inc. | 3 | $83 |
| Companion Medical, Inc. | 4 | $80 |
| Senseonics, Incorporated | 2 | $51 |
| Tolmar, Inc. | 2 | $37 |
| Merck | 2 | $31 |
| Aimmune Therapeutics, Inc. | 1 | $23 |
| Sequel Med Tech, LLC | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
| Pfizer | 1 | $12 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$1,751,968 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Kalamazoo
- Ulka VaishampayanAnn Arbor$33.7M
- Jeffrey PottsBay City$14.7M
- Neil FraserTroy$14.3M
- Abdulhassan SaadDearborn$11.5M
- Leslie PelkeyGrand Rapids$8.5M
- Jay SandbergTroy$8.3M
- Ding WangDetroit$6.8M
- Dipenkumar ModiDetroit$4.1M
- Ahmed ArifFlint$4.1M
- Sudipto MukherjeeRoyal Oak$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.